Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys 67,434 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 67,434 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were purchased at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the acquisition, the chief executive officer now directly owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. This represents a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The shares were bought at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.56 per share, for a total transaction of $780,000.00.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.74 on Friday. The stock’s fifty day moving average is $1.55 and its two-hundred day moving average is $1.55. The company has a market capitalization of $1.19 billion, a PE ratio of -9.16 and a beta of 1.63. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 52 week low of $0.86 and a 52 week high of $1.84.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. As a group, analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on OPK shares. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. Rubric Capital Management LP grew its position in shares of OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Millennium Management LLC lifted its stake in shares of OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC lifted its stake in shares of OPKO Health by 143.6% during the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd purchased a new stake in shares of OPKO Health during the 4th quarter worth $2,082,000. Finally, Norges Bank purchased a new stake in shares of OPKO Health during the 4th quarter worth $1,657,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.